David S. Krause

2.2k total citations · 2 hit papers
15 papers, 1.5k citations indexed

About

David S. Krause is a scholar working on Pharmacology, Infectious Diseases and Pharmacology. According to data from OpenAlex, David S. Krause has authored 15 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 5 papers in Infectious Diseases and 3 papers in Pharmacology. Recurrent topics in David S. Krause's work include Pharmacogenetics and Drug Metabolism (7 papers), Antifungal resistance and susceptibility (3 papers) and Vector-borne infectious diseases (2 papers). David S. Krause is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Antifungal resistance and susceptibility (3 papers) and Vector-borne infectious diseases (2 papers). David S. Krause collaborates with scholars based in United States, Italy and Canada. David S. Krause's co-authors include Beth P. Goldstein, Michele Wible, Annette C. Reboli, Coleman Rotstein, Deepali Kumar, Daniel H. Kett, Thomas J. Walsh, Robert F. Betts, Jennifer Schranz and Peter G. Pappas and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

David S. Krause

12 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anidulafungin versus Fluconazole for Invasive Candidiasis

2007 618 citations Annette C. Reboli, Coleman Rotstein et al. New England Journal of Medicine profile →
Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with Adjuvant

1998 509 citations Allen C. Steere, Vijay K. Sikand et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by David S. Krause

Since Specialization

Citations

This map shows the geographic impact of David S. Krause's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Krause with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Krause more than expected).

Fields of papers citing papers by David S. Krause

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Krause. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Krause. The network helps show where David S. Krause may publish in the future.

Co-authorship network of co-authors of David S. Krause

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Krause. A scholar is included among the top collaborators of David S. Krause based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Krause. David S. Krause is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study 2025 ·Journal of Personalized Medicine ·(unknown), (unknown), (unknown), J. D. Plummer, (unknown), David S. Krause, (unknown)	0
2	Use of a Consultation Service Following Pharmacogenetic Testing in Psychiatry 2022 ·Pharmacogenomics ·David S. Krause, (unknown)	3
3	Predicting Potential Drug-Drug-Gene Interactions in a Population of Individuals Utilizing a Community-Based Pharmacy 2022 ·CNS Spectrums ·(unknown), Gabriela Williams, David S. Krause, Stephen Clarke, (unknown), Jeffrey Botbyl, Stephen R. Saklad	0
4	Use of a Consultation Service Following Pharmacogenomic Testing in Psychiatry 2021 ·CNS Spectrums ·(unknown), David S. Krause	2
5	Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder 2020 ·Depression and Anxiety ·Roy H. Perlis, (unknown), Maurizio Fava, Todd Lencz, David S. Krause	38
6	Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population 2020 ·Christopher D. King, Agustin Yip, Ying Cao, (unknown), David S. Krause, (unknown), Kerry J. Ressler	4
7	19 Real World Patient-Reported Outcomes Following Pharmacogenomic Testing 2019 ·CNS Spectrums ·(unknown), Jennifer Ma, (unknown), (unknown), (unknown), David S. Krause	0
8	Anidulafungin versus Fluconazole for Invasive Candidiasis breakdown → 2007 ·New England Journal of Medicine ·Annette C. Reboli, Coleman Rotstein, Peter G. Pappas, Stanley W. Chapman, Daniel H. Kett, Deepali Kumar, Robert F. Betts, Michele Wible, Beth P. Goldstein, Jennifer Schranz, David S. Krause, Thomas J. Walsh	618
9	A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal Candidiasis 2004 ·Clinical Infectious Diseases ·David S. Krause, A. E. Simjee, C.E.J. Van Rensburg, (unknown), T. J. Walsh, Beth P. Goldstein, Michele Wible, Tim Henkel	169
10	Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia 2004 ·Antimicrobial Agents and Chemotherapy ·David S. Krause, John F. Reinhardt, José A. Vázquez, Annette C. Reboli, Beth P. Goldstein, Michele Wible, Timothy Henkel	129
11	Dalbavancin pharmacokinetics in subjects with mild or moderate hepatic impairment 2003 ·James A. Dowell, Elyse Seltzer, Martin Stogniew, (unknown), (unknown), David S. Krause, Tim Henkel	1
12	Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with Adjuvant breakdown → 1998 ·New England Journal of Medicine ·Allen C. Steere, Vijay K. Sikand, François Meurice, Dennis Parenti, Erol Fikrig, Robert T. Schoen, John Nowakowski, Christopher H. Schmid, (unknown), Charles Buscarino, David S. Krause	509
13	Specific Issues in the Design and Implementation of an Efficacy Trial for a Lyme Disease Vaccine 1997 ·Clinical Infectious Diseases ·François Meurice, Dennis Parenti, (unknown), David S. Krause	10
14	Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults 1995 ·Vaccine ·Vinod K. Rustgi, Charles J. Schleupner, David S. Krause	18
15	[Facilitation and safe-guarding of intestinal absorption of G-strophanthin with sodium lauryl sulfate]. 1955 ·PubMed ·David S. Krause	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact